MECOM and acute myeloid leukemia: Finally, atRA increased the quiescence of human AML cell lines retaining some stem cell characteristics in an EVI1-dependent manner, and enhanced clonogenicity and LSCe quiescence of primary EVI1 overexpressing, but not EVI1-negative, AML samples [17].